Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.

Autor: Giovane RA; Department of Family Medicine, Regional Medical Center of Central Alabama, Greenville, Alabama, USA., Rezai S; Department of OB/GYN, Valley Community Healthcare, North Hollywood, California, USA., Cleland E; Department of Family Medicine, University of Alabama, Tuscaloosa, Alabama, USA., Henderson CE; Garden OB/GYN, Mercy Medical Center, New York, New York, USA.
Jazyk: angličtina
Zdroj: Reviews in medical virology [Rev Med Virol] 2020 Sep; Vol. 30 (5), pp. e2136. Date of Electronic Publication: 2020 Jul 09.
DOI: 10.1002/rmv.2136
Abstrakt: SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.
(© 2020 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: